XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Goodwill and Intangible Assets
3 Months Ended
Mar. 31, 2023
Goodwill and Intangible Assets  
Goodwill and Intangible Assets

Note 9. Goodwill and Intangible Assets

The table below shows the weighted-average life, original cost, accumulated amortization, and net book value by major intangible asset classification:

Weighted-Average

Accumulated

 

    

Life (Years)

    

Original Cost

    

Amortization

    

Net Book Value

 

(in thousands)

 

Definite-lived intangible assets

IMS (UK) international product rights

10

$

8,655

$

5,770

$

2,885

Patents

 

12

 

486

366

 

120

Land-use rights

 

39

 

2,540

766

 

1,774

Subtotal

 

11

 

11,681

 

6,902

 

4,779

Indefinite-lived intangible assets

Trademark

 

*

 

29,225

 

 

29,225

Goodwill - Finished pharmaceutical products

 

*

 

3,175

 

 

3,175

Subtotal

 

*

 

32,400

 

 

32,400

As of March 31, 2023

 

*

$

44,081

$

6,902

$

37,179

Weighted-Average

Accumulated

 

    

Life (Years)

    

Original Cost

    

Amortization

    

Net Book Value

 

(in thousands)

 

Definite-lived intangible assets

IMS (UK) international product rights

10

$

8,462

$

5,430

$

3,032

Patents

 

12

 

486

362

 

124

Land-use rights

 

39

 

2,540

749

 

1,791

Subtotal

 

11

 

11,488

 

6,541

 

4,947

Indefinite-lived intangible assets

Trademark

 

*

 

29,225

 

 

29,225

Goodwill - Finished pharmaceutical products

 

*

 

3,126

 

 

3,126

Subtotal

 

*

 

32,351

 

 

32,351

As of December 31, 2022

 

*

$

43,839

$

6,541

$

37,298

*

Intangible assets with indefinite lives have an indeterminable average life.

Goodwill

The changes in the carrying amounts of goodwill are as follows:

March 31, 

December 31, 

 

2023

2022

 

(in thousands)

 

Beginning balance

    

$

3,126

    

$

3,313

Currency translation

 

49

 

(187)

Ending balance

$

3,175

$

3,126

Primatene® Trademark

In January 2009, the Company acquired the exclusive rights to the trademark, domain name, website and domestic marketing, distribution and selling rights related to Primatene MIST®, an over-the-counter bronchodilator product, recorded at the allocated fair value of $29.2 million, which is its carrying value as of March 31, 2023.

The trademark was determined to have an indefinite life. In determining its indefinite life, the Company considered the following: the expected use of the intangible; the longevity of the brand; the legal, regulatory and contractual provisions that affect their maximum useful life; the Company’s ability to renew or extend the asset’s legal or contractual life without substantial costs; effects of the regulatory environment; expected changes in distribution channels; maintenance expenditures required to obtain the expected future cash flows from the asset; and considerations for obsolescence, demand, competition and other economic factors.